Joaquin(Bellmunt)Bellmunt MolinsMDPhD

Summary

• Dr. Joaquim Bellmunt is Associate Professor of Medicine at Harvard Medical School and Attending Physician of Solid Tumor Oncology at Beth Israel Deaconess Medical Center. He also serves as the Director of the Bladder Cancer Program at BIDMC , Harvard University, Boston working as part of a multidisciplinary team to provide complete care for patients with genitourinary malignancies. He is past chairman of the Committee of Advanced Bladder Cancer in the European Organization for Research and Treatment of Cancer (EORTC) Genitourinary Group (EORTC-GU). He is co-founder and has been President of the Spanish Group for Treatment of Genitourinary Tumors (SOGUG). Dr Bellmunt's efforts have largely centered on improving the care of patients with genitourinary malignancies focusing on bladder and renal cell carcinoma.
  
  His areas of interest in genitourinary oncology include the development of drugs directed to novel therapeutic targets and early clinical and translational research in the field of growth factor receptors and angiogenesis. While his research interests are focused on bladder cancer, he has extensive experience treating prostate, penile, and kidney cancer. He serves on International committees focused on improving the treatments of genitourinary and bladder cancers. He is a member of the Editorial Board of the Journal of Clinical Oncology and European Urology.
  
  He has been chairing two of the larger multicenter international trials of new drugs in the treatment of bladder cancer, in one of them, leading to the establishment of a new drug for bladder cancer patients. Dr Bellmunt's research focuses on clinical trials with aims to improve the treatment of patients with advanced bladder (urothelial) tumors as well as the development of novel agents for this disease. Dr Bellmunt is currently involved in collaborative efforts with basic scientists to analyze clinical, tissue, and biomarkers to optimize the administration